Design of targeted cardiovascular molecular imaging probes

Carolyn J. Anderson, Jeff W Bulte, Kai Chen, Xiaoyuan Chen, Ban An Khaw, Monica Shokeen, Karen L. Wooley, Henry F. VanBrocklin

Research output: Contribution to journalArticle

Abstract

Molecular imaging relies on the development of sensitive and specific probes coupled with imaging hardware and software to provide information about the molecular status of a disease and its response to therapy, which are important aspects of disease management. As genomic and proteomic information from a variety of cardiovascular diseases becomes available, new cellular and molecular targets will provide an imaging readout of fundamental disease processes. A review of the development and application of several cardiovascular probes is presented here. Strategies for labeling cells with superparamagnetic iron oxide nanoparticles enable monitoring of the delivery of stem cell therapies. Small molecules and biologics (e.g., proteins and antibodies) with high affinity and specificity for cell surface receptors or cellular proteins as well as enzyme substrates or inhibitors may be labeled with single-photon-emitting or positronemitting isotopes for nuclear molecular imaging applications. Labeling of bispecific antibodies with single-photon-emitting isotopes coupled with a pretargeting strategy may be used to enhance signal accumulation in small lesions. Emerging nanomaterials will provide platforms that have various sizes and structures and that may be used to develop multimeric, multimodal molecular imaging agents to probe one or more targets simultaneously. These platforms may be chemically manipulated to afford molecules with specific targeting and clearance properties. These examples of molecular imaging probes are characteristic of the multidisciplinary nature of the extraction of advanced biochemical information that will enhance diagnostic evaluation and drug development and predict clinical outcomes, fulfilling the promise of personalized medicine and improved patient care.

Original languageEnglish (US)
JournalJournal of Nuclear Medicine
Volume51
Issue numberSUPPL.1
DOIs
StatePublished - 2010

Fingerprint

Molecular Probes
Molecular Imaging
Photons
Isotopes
Multimodal Imaging
Bispecific Antibodies
Precision Medicine
Drug Evaluation
Nanostructures
Cell Surface Receptors
Disease Management
Cell- and Tissue-Based Therapy
Biological Products
Proteomics
Nanoparticles
Patient Care
Proteins
Cardiovascular Diseases
Stem Cells
Software

Keywords

  • Bispecific antibodies
  • Molecular imaging
  • Multimeric molecular imaging agents
  • Nanomaterials
  • Nanoparticles
  • Superparamagnetic iron oxide

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Anderson, C. J., Bulte, J. W., Chen, K., Chen, X., Khaw, B. A., Shokeen, M., ... VanBrocklin, H. F. (2010). Design of targeted cardiovascular molecular imaging probes. Journal of Nuclear Medicine, 51(SUPPL.1). https://doi.org/10.2967/jnumed.109.068130

Design of targeted cardiovascular molecular imaging probes. / Anderson, Carolyn J.; Bulte, Jeff W; Chen, Kai; Chen, Xiaoyuan; Khaw, Ban An; Shokeen, Monica; Wooley, Karen L.; VanBrocklin, Henry F.

In: Journal of Nuclear Medicine, Vol. 51, No. SUPPL.1, 2010.

Research output: Contribution to journalArticle

Anderson, CJ, Bulte, JW, Chen, K, Chen, X, Khaw, BA, Shokeen, M, Wooley, KL & VanBrocklin, HF 2010, 'Design of targeted cardiovascular molecular imaging probes', Journal of Nuclear Medicine, vol. 51, no. SUPPL.1. https://doi.org/10.2967/jnumed.109.068130
Anderson, Carolyn J. ; Bulte, Jeff W ; Chen, Kai ; Chen, Xiaoyuan ; Khaw, Ban An ; Shokeen, Monica ; Wooley, Karen L. ; VanBrocklin, Henry F. / Design of targeted cardiovascular molecular imaging probes. In: Journal of Nuclear Medicine. 2010 ; Vol. 51, No. SUPPL.1.
@article{981d8bd4c2bd471a8d9a0bb504e329ce,
title = "Design of targeted cardiovascular molecular imaging probes",
abstract = "Molecular imaging relies on the development of sensitive and specific probes coupled with imaging hardware and software to provide information about the molecular status of a disease and its response to therapy, which are important aspects of disease management. As genomic and proteomic information from a variety of cardiovascular diseases becomes available, new cellular and molecular targets will provide an imaging readout of fundamental disease processes. A review of the development and application of several cardiovascular probes is presented here. Strategies for labeling cells with superparamagnetic iron oxide nanoparticles enable monitoring of the delivery of stem cell therapies. Small molecules and biologics (e.g., proteins and antibodies) with high affinity and specificity for cell surface receptors or cellular proteins as well as enzyme substrates or inhibitors may be labeled with single-photon-emitting or positronemitting isotopes for nuclear molecular imaging applications. Labeling of bispecific antibodies with single-photon-emitting isotopes coupled with a pretargeting strategy may be used to enhance signal accumulation in small lesions. Emerging nanomaterials will provide platforms that have various sizes and structures and that may be used to develop multimeric, multimodal molecular imaging agents to probe one or more targets simultaneously. These platforms may be chemically manipulated to afford molecules with specific targeting and clearance properties. These examples of molecular imaging probes are characteristic of the multidisciplinary nature of the extraction of advanced biochemical information that will enhance diagnostic evaluation and drug development and predict clinical outcomes, fulfilling the promise of personalized medicine and improved patient care.",
keywords = "Bispecific antibodies, Molecular imaging, Multimeric molecular imaging agents, Nanomaterials, Nanoparticles, Superparamagnetic iron oxide",
author = "Anderson, {Carolyn J.} and Bulte, {Jeff W} and Kai Chen and Xiaoyuan Chen and Khaw, {Ban An} and Monica Shokeen and Wooley, {Karen L.} and VanBrocklin, {Henry F.}",
year = "2010",
doi = "10.2967/jnumed.109.068130",
language = "English (US)",
volume = "51",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "SUPPL.1",

}

TY - JOUR

T1 - Design of targeted cardiovascular molecular imaging probes

AU - Anderson, Carolyn J.

AU - Bulte, Jeff W

AU - Chen, Kai

AU - Chen, Xiaoyuan

AU - Khaw, Ban An

AU - Shokeen, Monica

AU - Wooley, Karen L.

AU - VanBrocklin, Henry F.

PY - 2010

Y1 - 2010

N2 - Molecular imaging relies on the development of sensitive and specific probes coupled with imaging hardware and software to provide information about the molecular status of a disease and its response to therapy, which are important aspects of disease management. As genomic and proteomic information from a variety of cardiovascular diseases becomes available, new cellular and molecular targets will provide an imaging readout of fundamental disease processes. A review of the development and application of several cardiovascular probes is presented here. Strategies for labeling cells with superparamagnetic iron oxide nanoparticles enable monitoring of the delivery of stem cell therapies. Small molecules and biologics (e.g., proteins and antibodies) with high affinity and specificity for cell surface receptors or cellular proteins as well as enzyme substrates or inhibitors may be labeled with single-photon-emitting or positronemitting isotopes for nuclear molecular imaging applications. Labeling of bispecific antibodies with single-photon-emitting isotopes coupled with a pretargeting strategy may be used to enhance signal accumulation in small lesions. Emerging nanomaterials will provide platforms that have various sizes and structures and that may be used to develop multimeric, multimodal molecular imaging agents to probe one or more targets simultaneously. These platforms may be chemically manipulated to afford molecules with specific targeting and clearance properties. These examples of molecular imaging probes are characteristic of the multidisciplinary nature of the extraction of advanced biochemical information that will enhance diagnostic evaluation and drug development and predict clinical outcomes, fulfilling the promise of personalized medicine and improved patient care.

AB - Molecular imaging relies on the development of sensitive and specific probes coupled with imaging hardware and software to provide information about the molecular status of a disease and its response to therapy, which are important aspects of disease management. As genomic and proteomic information from a variety of cardiovascular diseases becomes available, new cellular and molecular targets will provide an imaging readout of fundamental disease processes. A review of the development and application of several cardiovascular probes is presented here. Strategies for labeling cells with superparamagnetic iron oxide nanoparticles enable monitoring of the delivery of stem cell therapies. Small molecules and biologics (e.g., proteins and antibodies) with high affinity and specificity for cell surface receptors or cellular proteins as well as enzyme substrates or inhibitors may be labeled with single-photon-emitting or positronemitting isotopes for nuclear molecular imaging applications. Labeling of bispecific antibodies with single-photon-emitting isotopes coupled with a pretargeting strategy may be used to enhance signal accumulation in small lesions. Emerging nanomaterials will provide platforms that have various sizes and structures and that may be used to develop multimeric, multimodal molecular imaging agents to probe one or more targets simultaneously. These platforms may be chemically manipulated to afford molecules with specific targeting and clearance properties. These examples of molecular imaging probes are characteristic of the multidisciplinary nature of the extraction of advanced biochemical information that will enhance diagnostic evaluation and drug development and predict clinical outcomes, fulfilling the promise of personalized medicine and improved patient care.

KW - Bispecific antibodies

KW - Molecular imaging

KW - Multimeric molecular imaging agents

KW - Nanomaterials

KW - Nanoparticles

KW - Superparamagnetic iron oxide

UR - http://www.scopus.com/inward/record.url?scp=77953075333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953075333&partnerID=8YFLogxK

U2 - 10.2967/jnumed.109.068130

DO - 10.2967/jnumed.109.068130

M3 - Article

C2 - 20395345

AN - SCOPUS:77953075333

VL - 51

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - SUPPL.1

ER -